NeuroSense Therapeutics Ltd. (NRSNW) Comparison with companies in other sectors?

NeuroSense Therapeutics Ltd. has a share price of 23.99M. You can analyze NeuroSense Therapeutics Ltd. (NRSNW) competitors across different market sectors through stock heatmaps.

What are NRSNW's NET and operating margins?

NeuroSense Therapeutics Ltd. (NRSNW) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does NRSNW's earnings per share (EPS) trend reflect its financial momentum?

NeuroSense Therapeutics Ltd. (NRSNW) EPS is -0.94 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for NeuroSense Therapeutics Ltd. is -0.95, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for NeuroSense Therapeutics Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for NeuroSense Therapeutics Ltd. like P/E which is -4.55, P/B which is 17.97, and PEG which is -0.32. Compare them with sector averages to evaluate if the stock is priced fairly.

NeuroSense Therapeutics Ltd.

NRSNW•NASDAQ

Healthcare

Biotechnology

$0.89

$0.09(11.03%)

Fundamental Analysis of NeuroSense Therapeutics Ltd. (NRSNW)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.94

P/E Ratio

-0.95

ROE

4.57%

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$21.35M

Shares OutstandingTotal number of shares issued

$23.99M

Book Value/ShareNet worth per share

$0.11

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.935

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

457.28%

ROAReturn on total assets

-223.17%

ROCEReturn on capital employed

-383.35%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

Cash/ShareCash and equivalents per share

$0.15

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for NRSNWFinancial Ratios Analysis details for NRSNW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for NRSNWSector Benchmarking details for NRSNW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for NeuroSense Therapeutics Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of NeuroSense Therapeutics Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account NeuroSense Therapeutics Ltd.'s unique business strengths and challenges.

Key Financial Metrics for NeuroSense Therapeutics Ltd.

For NeuroSense Therapeutics Ltd., essential financial indicators include EPS -0.94, PE -0.95, and ROE 4.57. These key ratios reveal insights into NeuroSense Therapeutics Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare NeuroSense Therapeutics Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of NeuroSense Therapeutics Ltd.

Metrics like Net Margin - and ROA -223.17% shed light on how well NeuroSense Therapeutics Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether NeuroSense Therapeutics Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of NeuroSense Therapeutics Ltd.

Using ratios such as P/B Ratio 17.97 and PEG Ratio -0.32, investors can assess whether NeuroSense Therapeutics Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with NeuroSense Therapeutics Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for NeuroSense Therapeutics Ltd.

Financial health indicators, such as Debt/Equity Ratio 0.03 and Cash Flow -, provide a snapshot of NeuroSense Therapeutics Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like NeuroSense Therapeutics Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for NeuroSense Therapeutics Ltd.

Investing in NeuroSense Therapeutics Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at NeuroSense Therapeutics Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;